Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Trinity Biotech (TRIB) Income from Continuing Operations (2016 - 2024)

Trinity Biotech's Income from Continuing Operations history spans 16 years, with the latest figure at 15797000.0 for Q4 2024.

  • On a quarterly basis, Income from Continuing Operations fell 193.08% to 15797000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 30665000.0, a 15.56% increase, with the full-year FY2025 number at 37376000.0, down 19.73% from a year prior.
  • Income from Continuing Operations hit 15797000.0 in Q4 2024 for Trinity Biotech, down from 4794000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for TRIB hit a ceiling of 10687000.0 in Q3 2020 and a floor of 18324000.0 in Q2 2023.
  • Historically, Income from Continuing Operations has averaged 4075750.0 across 5 years, with a median of 5092000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 511.27% in 2020 and later crashed 2026.0% in 2022.
  • Tracing TRIB's Income from Continuing Operations over 5 years: stood at 10361000.0 in 2020, then tumbled by 132.48% to 3365000.0 in 2021, then tumbled by 210.31% to 10442000.0 in 2022, then soared by 48.38% to 5390000.0 in 2023, then crashed by 193.08% to 15797000.0 in 2024.
  • Business Quant data shows Income from Continuing Operations for TRIB at 15797000.0 in Q4 2024, 4794000.0 in Q3 2024, and 6891000.0 in Q2 2024.